You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRemikiren
Accession NumberDB00212  (APRD00163)
TypeSmall Molecule
GroupsApproved
DescriptionRemikiren is an orally active, high specificity renin inhibitor.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • Ro 42-5892
  • RO-42-5892
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIILC7FBL96A4
CAS number126222-34-2
WeightAverage: 630.838
Monoisotopic: 630.345106042
Chemical FormulaC33H50N4O6S
InChI KeyUXIGZRQVLGFTOU-VQXQMPIVSA-N
InChI
InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1
IUPAC Name
(2S)-2-{[(2S)-2-benzyl-1-hydroxy-3-(2-methylpropane-2-sulfonyl)propylidene]amino}-N-[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanimidic acid
SMILES
[H][C@@](CC1=CC=CC=C1)(CS(=O)(=O)C(C)(C)C)C(O)=N[C@@]([H])(CC1=CN=CN1)C(O)=N[C@@]([H])(CC1CCCCC1)[C@@]([H])(O)[C@@]([H])(O)C1CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Imidazole
  • Azole
  • Secondary alcohol
  • 1,2-diol
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidic acid derivative
  • Carboximidic acid
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension and heart failure
PharmacodynamicsRemikiren is an orally available renin inhibitor with an established blood pressure-lowering effect in patients with essential hypertension. No data are available on the renal effects of remikiren in humans. In patients with essential hypertension, a single oral dose of remikiren can induce a renal vasodilation, without affecting the GFR and despite a significant decrease in blood pressure. This systemic and renal hemodynamic response is more pronounced in case of a more activated renin-angiotensin system.
Mechanism of actionSeveral in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism.
Related Articles
AbsorptionAbsorbed following oral administration.
Volume of distributionNot Available
Protein binding83%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8744
Blood Brain Barrier-0.8746
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7043
P-glycoprotein inhibitor INon-inhibitor0.6427
P-glycoprotein inhibitor IINon-inhibitor0.9732
Renal organic cation transporterNon-inhibitor0.8832
CYP450 2C9 substrateNon-substrate0.5243
CYP450 2D6 substrateNon-substrate0.7775
CYP450 3A4 substrateSubstrate0.5695
CYP450 1A2 substrateNon-inhibitor0.8245
CYP450 2C9 inhibitorNon-inhibitor0.6456
CYP450 2D6 inhibitorNon-inhibitor0.8548
CYP450 2C19 inhibitorNon-inhibitor0.6534
CYP450 3A4 inhibitorInhibitor0.8648
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6298
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7601
BiodegradationNot ready biodegradable0.9754
Rat acute toxicity2.5600 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9958
hERG inhibition (predictor II)Non-inhibitor0.5881
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.9Not Available
Caco2 permeability-6.13ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP3.56ALOGPS
logP3.22ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)5.47ChemAxon
pKa (Strongest Basic)6.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area168.46 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity170.64 m3·mol-1ChemAxon
Polarizability68.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Clozel JP, Fischli W: Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung. 1993 Feb;43(2A):260-2. [PubMed:8498974 ]
  2. Richter WF, Whitby BR, Chou RC: Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica. 1996 Mar;26(3):243-54. [PubMed:8730917 ]
External Links
ATC CodesC09XA01
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Remikiren.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Remikiren.
AcebutololRemikiren may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Remikiren.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Remikiren.
AliskirenRemikiren may increase the hypotensive activities of Aliskiren.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Remikiren.
AlprenololRemikiren may increase the hypotensive activities of Alprenolol.
AmbrisentanRemikiren may increase the hypotensive activities of Ambrisentan.
AmifostineRemikiren may increase the hypotensive activities of Amifostine.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Remikiren.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Remikiren.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Remikiren.
AmlodipineRemikiren may increase the hypotensive activities of Amlodipine.
AtenololRemikiren may increase the hypotensive activities of Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Remikiren.
BenazeprilRemikiren may increase the hypotensive activities of Benazepril.
BendroflumethiazideRemikiren may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Remikiren.
BepridilRemikiren may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Remikiren.
BethanidineRemikiren may increase the hypotensive activities of Bethanidine.
BimatoprostRemikiren may increase the hypotensive activities of Bimatoprost.
BisoprololRemikiren may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Remikiren can be decreased when it is combined with Boceprevir.
BosentanRemikiren may increase the hypotensive activities of Bosentan.
BretyliumRemikiren may increase the hypotensive activities of Bretylium.
BrimonidineRemikiren may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Remikiren.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Remikiren.
BupranololRemikiren may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Remikiren.
CandesartanRemikiren may increase the hypotensive activities of Candesartan.
CandoxatrilRemikiren may increase the hypotensive activities of Candoxatril.
CaptoprilRemikiren may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Remikiren can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Remikiren.
CarteololRemikiren may increase the hypotensive activities of Carteolol.
CarvedilolRemikiren may increase the hypotensive activities of Carvedilol.
CeliprololRemikiren may increase the hypotensive activities of Celiprolol.
ChlorothiazideRemikiren may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneRemikiren may increase the hypotensive activities of Chlorthalidone.
CilazaprilRemikiren may increase the hypotensive activities of Cilazapril.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Remikiren.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Remikiren.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Remikiren.
ClonidineRemikiren may increase the hypotensive activities of Clonidine.
CryptenamineRemikiren may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Remikiren.
CyclophosphamideThe risk or severity of adverse effects can be increased when Remikiren is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Remikiren.
CyclothiazideRemikiren may increase the hypotensive activities of Cyclothiazide.
DebrisoquinRemikiren may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Remikiren.
DeserpidineRemikiren may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Remikiren.
DiazoxideDiazoxide may increase the hypotensive activities of Remikiren.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Remikiren.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Remikiren.
DiltiazemRemikiren may increase the hypotensive activities of Diltiazem.
DorzolamideRemikiren may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Remikiren.
DoxazosinRemikiren may increase the hypotensive activities of Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Remikiren.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Remikiren.
EfonidipineRemikiren may increase the hypotensive activities of Efonidipine.
EnalaprilRemikiren may increase the hypotensive activities of Enalapril.
EnalaprilatRemikiren may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Remikiren.
EpoprostenolRemikiren may increase the hypotensive activities of Epoprostenol.
EprosartanRemikiren may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Remikiren.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Remikiren.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Remikiren.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Remikiren.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Remikiren.
FelodipineRemikiren may increase the hypotensive activities of Felodipine.
FenoldopamRemikiren may increase the hypotensive activities of Fenoldopam.
FosinoprilRemikiren may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Remikiren.
GarlicThe serum concentration of Remikiren can be decreased when it is combined with Garlic.
GuanabenzRemikiren may increase the hypotensive activities of Guanabenz.
GuanadrelRemikiren may increase the hypotensive activities of Guanadrel.
GuanethidineRemikiren may increase the hypotensive activities of Guanethidine.
GuanfacineRemikiren may increase the hypotensive activities of Guanfacine.
HexamethoniumRemikiren may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Remikiren.
HydralazineRemikiren may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideRemikiren may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideRemikiren may increase the hypotensive activities of Hydroflumethiazide.
IloprostIloprost may increase the hypotensive activities of Remikiren.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Remikiren.
IndapamideRemikiren may increase the hypotensive activities of Indapamide.
IndenololRemikiren may increase the hypotensive activities of Indenolol.
IndoraminRemikiren may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Remikiren.
IproniazidIproniazid may increase the hypotensive activities of Remikiren.
IrbesartanRemikiren may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Remikiren.
IsradipineRemikiren may increase the hypotensive activities of Isradipine.
LabetalolRemikiren may increase the hypotensive activities of Labetalol.
LacidipineRemikiren may increase the hypotensive activities of Lacidipine.
LatanoprostRemikiren may increase the hypotensive activities of Latanoprost.
LercanidipineRemikiren may increase the hypotensive activities of Lercanidipine.
LisinoprilRemikiren may increase the hypotensive activities of Lisinopril.
LofexidineRemikiren may increase the hypotensive activities of Lofexidine.
LosartanRemikiren may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Remikiren.
MacitentanRemikiren may increase the hypotensive activities of Macitentan.
ManidipineRemikiren may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Remikiren.
MecamylamineRemikiren may increase the hypotensive activities of Mecamylamine.
MethyldopaRemikiren may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Remikiren.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Remikiren.
MetipranololRemikiren may increase the hypotensive activities of Metipranolol.
MetolazoneRemikiren may increase the hypotensive activities of Metolazone.
MetoprololRemikiren may increase the hypotensive activities of Metoprolol.
MibefradilRemikiren may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Remikiren.
MinaprineMinaprine may increase the hypotensive activities of Remikiren.
MinoxidilRemikiren may increase the hypotensive activities of Minoxidil.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Remikiren.
MoclobemideMoclobemide may increase the hypotensive activities of Remikiren.
MoexiprilRemikiren may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Remikiren.
MoxonidineRemikiren may increase the hypotensive activities of Moxonidine.
NadololRemikiren may increase the hypotensive activities of Nadolol.
NebivololRemikiren may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Remikiren.
NialamideNialamide may increase the hypotensive activities of Remikiren.
NicardipineRemikiren may increase the hypotensive activities of Nicardipine.
NicorandilRemikiren may increase the hypotensive activities of Nicorandil.
NiguldipineRemikiren may increase the hypotensive activities of Niguldipine.
NilvadipineRemikiren may increase the hypotensive activities of Nilvadipine.
NimodipineRemikiren may increase the hypotensive activities of Nimodipine.
NisoldipineRemikiren may increase the hypotensive activities of Nisoldipine.
NitrendipineRemikiren may increase the hypotensive activities of Nitrendipine.
NitroprussideRemikiren may increase the hypotensive activities of Nitroprusside.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Remikiren.
ObinutuzumabRemikiren may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Remikiren.
OlmesartanRemikiren may increase the hypotensive activities of Olmesartan.
OmapatrilatRemikiren may increase the hypotensive activities of Omapatrilat.
OxprenololRemikiren may increase the hypotensive activities of Oxprenolol.
PargylineRemikiren may increase the hypotensive activities of Pargyline.
PenbutololRemikiren may increase the hypotensive activities of Penbutolol.
PentoliniumRemikiren may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Remikiren.
PerindoprilRemikiren may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Remikiren is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Remikiren.
PheniprazinePheniprazine may increase the hypotensive activities of Remikiren.
PhenoxybenzamineRemikiren may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Remikiren.
PhentolamineRemikiren may increase the hypotensive activities of Phentolamine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Remikiren.
PinacidilRemikiren may increase the hypotensive activities of Pinacidil.
PindololRemikiren may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Remikiren.
PivhydrazinePivhydrazine may increase the hypotensive activities of Remikiren.
PolythiazideRemikiren may increase the hypotensive activities of Polythiazide.
PrazosinRemikiren may increase the hypotensive activities of Prazosin.
PropranololRemikiren may increase the hypotensive activities of Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Remikiren.
QuinaprilRemikiren may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Remikiren.
RamiprilRamipril may increase the hypotensive activities of Remikiren.
RasagilineRasagiline may increase the hypotensive activities of Remikiren.
RescinnamineRemikiren may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Remikiren.
RiociguatRemikiren may increase the hypotensive activities of Riociguat.
RituximabRemikiren may increase the hypotensive activities of Rituximab.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Remikiren.
SafrazineSafrazine may increase the hypotensive activities of Remikiren.
SaprisartanRemikiren may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Remikiren.
SelexipagRemikiren may increase the hypotensive activities of Selexipag.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Remikiren.
SildenafilSildenafil may increase the antihypertensive activities of Remikiren.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Remikiren.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Remikiren.
SitaxentanRemikiren may increase the hypotensive activities of Sitaxentan.
SpiraprilRemikiren may increase the hypotensive activities of Spirapril.
St. John's WortThe metabolism of Remikiren can be increased when combined with St. John's Wort.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Remikiren.
TadalafilTadalafil may increase the antihypertensive activities of Remikiren.
TelmisartanRemikiren may increase the hypotensive activities of Telmisartan.
TemocaprilRemikiren may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Remikiren is combined with Temsirolimus.
TerlipressinRemikiren may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Remikiren.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Remikiren.
TiboloneRemikiren may increase the hypotensive activities of Tibolone.
TicrynafenRemikiren may increase the hypotensive activities of Ticrynafen.
TimololRemikiren may increase the hypotensive activities of Timolol.
TipranavirThe serum concentration of Remikiren can be decreased when it is combined with Tipranavir.
TolazolineRemikiren may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Remikiren.
TorasemideRemikiren may increase the hypotensive activities of Torasemide.
TrandolaprilRemikiren may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Remikiren.
TranylcypromineTranylcypromine may increase the hypotensive activities of Remikiren.
TravoprostRemikiren may increase the hypotensive activities of Travoprost.
TreprostinilRemikiren may increase the hypotensive activities of Treprostinil.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Remikiren.
TrichlormethiazideRemikiren may increase the hypotensive activities of Trichlormethiazide.
TrimazosinRemikiren may increase the hypotensive activities of Trimazosin.
TrimethaphanRemikiren may increase the hypotensive activities of Trimethaphan.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Remikiren.
UdenafilUdenafil may increase the antihypertensive activities of Remikiren.
UnoprostoneRemikiren may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Remikiren.
VardenafilVardenafil may increase the antihypertensive activities of Remikiren.
XylometazolineRemikiren may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Remikiren.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Remikiren.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.
Gene Name:
REN
Uniprot ID:
P00797
Molecular Weight:
45057.125 Da
References
  1. van Paassen P, Navis GJ, De Jong PE, De Zeeuw D: Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. Eur J Clin Invest. 1999 Dec;29(12):1019-26. [PubMed:10583449 ]
  2. MacFadyen RJ, Jones CR, Doig JK, Birnbock H, Reid JL: Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. J Cardiovasc Pharmacol. 1995 Mar;25(3):347-53. [PubMed:7769797 ]
  3. Kiowski W, Beermann J, Rickenbacher P, Haemmerli R, Thomas M, Burkart F, Meinertz T: Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation. 1994 Dec;90(6):2748-56. [PubMed:7994817 ]
  4. Hilgers KF, Fischli W, Veelken R, Mann JF: Vascular renin in the guinea pig. Suppression by the renin inhibitor remikiren. Hypertension. 1994 Jun;23(6 Pt 2):861-4. [PubMed:8206619 ]
  5. Clozel JP, Fischli W: Comparative effects of three different potent renin inhibitors in primates. Hypertension. 1993 Jul;22(1):9-17. [PubMed:8319997 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23